Conference Proceedings

A phase II, open-label, randomized, multicenter trial of encorafenib plus binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS)

MA Davies, JS Weber, KT Flaherty, GA McArthur, MB Reddy, A Golden, JL Culbertson, CT Thomas, HA Tawbi, GV Long

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

University of Melbourne Researchers

Grants

Funding Acknowledgements

Array BioPharma Inc.